Jim Simons Biotechnology

Renaissance Technologies LLC

$70.6 Billion
Q3 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
UTHR United Therapeutics Corp	$21B	$911 Million 1.29% of portfolio	2,173,392	Q3 2025 Added 2.56%
EXEL Exelixis, Inc.	$13.8B	$638 Million 0.9% of portfolio	15,459,266	Q3 2025 Reduced 2.28%
CORT Corcept Therapeutics Inc	$8.46B	$506 Million 0.72% of portfolio	6,089,347	Q3 2025 Reduced 2.83%
INCY Incyte Corp	$23.4B	$384 Million 0.54% of portfolio	4,528,132	Q3 2025 Added 16.65%
VRTX Vertex Pharmaceuticals Inc	$112B	$288 Million 0.41% of portfolio	735,888	Q3 2025 Reduced 26.77%
NVO Novo Nordisk A S	$111B	$160 Million 0.23% of portfolio	2,881,996	Q3 2025 Reduced 41.62%
REGN Regeneron Pharmaceuticals, Inc.	$74.5B	$155 Million 0.22% of portfolio	275,162	Q3 2025 Added 510.63%
JAZZ Jazz Pharmaceuticals PLC	$8.88B	$122 Million 0.17% of portfolio	924,874	Q3 2025 Added 2.72%
BMRN Biomarin Pharmaceutical Inc	$10.1B	$103 Million 0.15% of portfolio	1,893,571	Q3 2025 Added 4.8%
GMAB Genmab A/S	$19.9B	$86.5 Million 0.12% of portfolio	2,821,543	Q3 2025 Added 1.98%
INVA Innoviva, Inc.	$1.53B	$83.7 Million 0.12% of portfolio	4,586,932	Q3 2025 Reduced 3.65%
HALO Halozyme Therapeutics, Inc.	$9.77B	$73.4 Million 0.1% of portfolio	1,000,209	Q3 2025 Added 195.39%
CPRX Catalyst Pharmaceuticals, Inc.	$2.38B	$69.8 Million 0.1% of portfolio	3,544,830	Q3 2025 Added 9.02%
VRNA Verona Pharma PLC	$6.52B	$65.7 Million 0.09% of portfolio	615,900	Q3 2025 Added 317.84%
PTCT Ptc Therapeutics, Inc.	$5.28B	$56.9 Million 0.08% of portfolio	927,300	Q3 2025 Reduced 3.74%
MDGL Madrigal Pharmaceuticals, Inc.	$9.26B	$55.4 Million 0.08% of portfolio	120,682	Q3 2025 Added 1,013.71%
RYTM Rhythm Pharmaceuticals, Inc.	$5.56B	$55.2 Million 0.08% of portfolio	546,593	Q3 2025 Added 73.58%
SRPT Sarepta Therapeutics, Inc.	$1.57B	$51.1 Million 0.07% of portfolio	2,650,178	Q3 2025 Added 324.38%
INSM Insmed Inc	$26.2B	$50.8 Million 0.07% of portfolio	352,887	Q3 2025 Added 14.32%
TVTX Travere Therapeutics, Inc.	$2.32B	$41.9 Million 0.06% of portfolio	1,752,114	Q3 2025 Reduced 29.78%
ADMA Adma Biologics, Inc.	$2.91B	$40.6 Million 0.06% of portfolio	2,770,442	Q3 2025 Reduced 11.94%
MIRM Mirum Pharmaceuticals, Inc.	$2.62B	$37.6 Million 0.05% of portfolio	513,448	Q3 2025 Added 29.54%
IONS Ionis Pharmaceuticals Inc	$10.3B	$31.8 Million 0.05% of portfolio	486,714	Q3 2025 Added 79.79%
HRMY Harmony Biosciences Holdings, Inc.	$1.95B	$31.3 Million 0.04% of portfolio	1,137,071	Q3 2025 Added 22.34%
ACAD Acadia Pharmaceuticals Inc	$3.84B	$30.9 Million 0.04% of portfolio	1,449,533	Q3 2025 Reduced 6.34%
LEGN Legend Biotech Corp	$5.19B	$27.5 Million 0.04% of portfolio	843,200	Q3 2025 Added 28.48%
AXSM Axsome Therapeutics, Inc.	$5.99B	$18.2 Million 0.03% of portfolio	150,000	Q3 2025 Added 8.15%
VNDA Vanda Pharmaceuticals Inc.	$248M	$17.3 Million 0.02% of portfolio	3,476,925	Q3 2025 Added 0.85%
ABCL Ab Cellera Biologics Inc.	$1.14B	$16.9 Million 0.02% of portfolio	3,360,729	Q3 2025 Added 1.61%
BBIO Bridge Bio Pharma, Inc.	$9.87B	$16.7 Million 0.02% of portfolio	322,246	Q3 2025 Added 31.02%
APLS Apellis Pharmaceuticals, Inc.	$2.14B	$16.4 Million 0.02% of portfolio	722,895	Q3 2025 Added 6,478.95%
BCRX Biocryst Pharmaceuticals Inc	$1.34B	$16.2 Million 0.02% of portfolio	2,140,534	Q3 2025 Reduced 15.28%
AUPH Aurinia Pharmaceuticals Inc.	$2.22B	$16 Million 0.02% of portfolio	1,449,600	Q3 2025 Added 25.2%
CYTK Cytokinetics Inc	$6.26B	$15.9 Million 0.02% of portfolio	289,967	Q3 2025 Added 2,752.04%
FOLD Amicus Therapeutics, Inc.	$2.61B	$15.3 Million 0.02% of portfolio	1,943,171	Q3 2025 Reduced 3.5%
MDXG Mimedx Group, Inc.	$867M	$14 Million 0.02% of portfolio	2,008,227	Q3 2025 Reduced 4.72%
SNDX Syndax Pharmaceuticals Inc	$1B	$13.2 Million 0.02% of portfolio	860,500	Q3 2025 Added 2.72%
XERS Xeris Biopharma Holdings, Inc.	$1B	$13.1 Million 0.02% of portfolio	1,622,840	Q3 2025 Reduced 21.04%
MRVI Maravai Lifesciences Holdings, Inc.	$428M	$12.4 Million 0.02% of portfolio	4,318,089	Q3 2025 Added 3.15%
GLPG Galapagos Nv	$2.16B	$12.3 Million 0.02% of portfolio	356,200	Q3 2025 Reduced 23.35%
RVMD Revolution Medicines, Inc.	$5.62B	$11.8 Million 0.02% of portfolio	253,104	Q3 2025 Added 3.94%
NTLA Intellia Therapeutics, Inc.	$774M	$11.2 Million 0.02% of portfolio	651,000	Q3 2025 Reduced 3.83%
LQDA Liquidia Corp	$1.77B	$11.1 Million 0.02% of portfolio	484,753	Q3 2025 New
PBYI Puma Biotechnology, Inc.	$231M	$11 Million 0.02% of portfolio	2,151,213	Q3 2025 Added 14.75%
AKBA Akebia Therapeutics, Inc.	$333M	$10.7 Million 0.02% of portfolio	3,952,727	Q3 2025 Reduced 5.76%
NVAX Novavax Inc	$582M	$10.4 Million 0.01% of portfolio	1,196,750	Q3 2025 Added 79.25%
CELC Celcuity Inc.	$1.17B	$9.57 Million 0.01% of portfolio	194,800	Q3 2025 Added 1,387.02%
ARDX Ardelyx, Inc.	$948M	$9.33 Million 0.01% of portfolio	1,690,093	Q3 2025 Added 29.89%
CTMX Cytom X Therapeutics, Inc.	$273M	$8.12 Million 0.01% of portfolio	2,545,260	Q3 2025 Added 36.68%
AUTL Autolus Therapeutics PLC	$134M	$8.01 Million 0.01% of portfolio	4,881,372	Q3 2025 Added 178.74%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account